IL33 and asthma: Considering the complicated inflammatory network in patients in cluster 3, developing biologics targeting the factor/s (for example, IL-33, IL-5, IL-13, and TNF-α), which may play a central role in the pathophysiology of disease in these patients, should lead to improvement of both the treatment and prognosis of patients with comorbid asthma and CRS.